Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis

作者全名："Zhang, Huan; Zhou, Weiying; Wang, Jin; Cai, Yun"

作者地址："[Zhang, Huan; Wang, Jin; Cai, Yun] Peoples Liberat Army Gen Hosp, Dept Pharm, Ctr Med Clin Res, Beijing 100853, Peoples R China; [Zhang, Huan; Zhou, Weiying] Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China"

通信作者："Cai, Y (corresponding author), 28 Fu Xing Rd, Beijing 100853, Peoples R China."

来源：JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000663802400007

JCR分区：Q2

影响因子：4.6

年份：2021

卷号：25

期号：　

开始页：380

结束页：389

文献类型：Review

关键词：Oritavancin; Acute bacterial skin and skin-structure infection; ABSSSI; Efficacy; Safety; Meta-analysis

摘要："Objectives: This study aimed to evaluate the efficacy and safety of oritavancin (ORI) versus comparators for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) based on available clinical studies. Methods: PubMed, Cochrane Library and Embase were searched from database inception to 28 July 2020 to identify clinical studies assessing the efficacy and safety of ORI and comparator antibiotics for the treatment of ABSSSIs. Primary efficacy outcome, investigator-assessed clinical cure, lesion size reduction >= 20%, additional post-treatment antibiotics, and 30-day emergency room (ER) visits and readmission were assessed as efficacy outcomes. Adverse events (AEs) and mortality were assessed as safety outcomes. I-2 statistic was calculated for heterogeneity, and a fixed-effects or random-effects model was used for estimation of the risk ratio (RR). Results: A total of 9213 patients from two randomised clinical trials (RCTs) and four cohort studies were included in this meta-analysis. ORI was statistically non-inferior to control agents in all efficacy and safety outcomes. Moreover, ORI significantly reduced the occurrence of 30-day readmission (RR = 0.42; P = 0.0004) and drug-related AEs (RR = 0.78; P = 0.002). In the subgroup analysis, ORI also had a lower rate of 30-day ER visits in the outpatient setting (RR = 0.34; P < 0.00 001). Conclusion: ORI was not inferior to comparators for the treatment of ABSSSIs. Meanwhile, it showed advantages in reducing the rate of readmission and drug-related AEs. More high-quality and large-scale RCTs are required to further confirm the efficacy and safety of ORI. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy."

基金机构：13th Five-Year Plan of National Major Science and Technology Projects [2018ZX09201-013]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81770004]

基金资助正文：This work was supported by the 13th Five-Year Plan of National Major Science and Technology Projects [grant number 2018ZX09201-013] and the National Natural Science Foundation of China [grant number 81770004].